Literature DB >> 25903576

High-Level Pan-Azole-Resistant Aspergillosis.

Jakko van Ingen1, Henrich A L van der Lee1, Antonius J M M Rijs1, Eveline Snelders1, Willem J G Melchers1, Paul E Verweij2.   

Abstract

High-level pan-azole-resistant Aspergillus fumigatus was recovered from four patients with chronic lung disease. In one patient, the development of progressive resistance followed long-term azole therapy and switching between antifungal azoles. The high-level pan-azole-resistant phenotypes were not associated with a specific cyp51A gene mutation. New strategies that avoid the development of progressive azole resistance are needed.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25903576      PMCID： PMC4473200          DOI： 10.1128/JCM.00502-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Roger J M Brüggemann; Paul E Verweij
Journal:  Drug Resist Updat       Date:  2014-07-05       Impact factor: 18.500

Review 2.  Azole resistance in Aspergillus fumigatus: a growing public health concern.

Authors:  Edith Vermeulen; Katrien Lagrou; Paul E Verweij
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

3.  Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

4.  Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter.

Authors:  Ahmed M Albarrag; Michael J Anderson; Susan J Howard; Geoff D Robson; Peter A Warn; Dominique Sanglard; David W Denning
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

5.  Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?

Authors:  Paul E Verweij; Eveline Snelders; Gert H J Kema; Emilia Mellado; Willem J G Melchers
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

6.  Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.

Authors:  Jakko van Ingen; Henrich A van der Lee; Ton A J Rijs; Jan Zoll; Tjalling Leenstra; Willem J G Melchers; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2014-10-09       Impact factor: 5.790

7.  High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease.

Authors:  David W Denning; Steven Park; Cornelia Lass-Florl; Marcin G Fraczek; Marie Kirwan; Robin Gore; Jaclyn Smith; Ahmed Bueid; Caroline B Moore; Paul Bowyer; David S Perlin
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 8.  Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope
Journal:  Drug Resist Updat       Date:  2014-01-27       Impact factor: 18.500

9.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

10.  In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.

Authors:  Lea Gregson; Joanne Goodwin; Adam Johnson; Laura McEntee; Caroline B Moore; Malcolm Richardson; William W Hope; Susan J Howard
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191
View more
  10 in total

Review 1.  Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.

Authors:  Anna Dudakova; Birgit Spiess; Marut Tangwattanachuleeporn; Christoph Sasse; Dieter Buchheidt; Michael Weig; Uwe Groß; Oliver Bader
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

2.  Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India.

Authors:  Yubhisha Dabas; Immaculata Xess; Sameer Bakshi; Manoranjan Mahapatra; Rachna Seth
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

3.  Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis.

Authors:  Cristina Jiménez-Ortigosa; Caroline Moore; David W Denning; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

4.  Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients.

Authors:  Patricia Postina; Julian Skladny; Tobias Boch; Oliver A Cornely; Axel Hamprecht; Peter-Michael Rath; Jörg Steinmann; Oliver Bader; Thomas Miethke; Anne Dietz; Natalia Merker; Wolf-Karsten Hofmann; Dieter Buchheidt; Birgit Spiess
Journal:  Front Microbiol       Date:  2018-03-27       Impact factor: 5.640

5.  cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex.

Authors:  Vanessa R Barrs; Jos Houbraken; Jessica J Talbot; Jens C Frisvad; Jacques F Meis; Ferry Hagen; Paul E Verweij; David E Hibbs; Felcia Lai; Paul W Groundwater; Robert A Samson; Sarah E Kidd
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

6.  Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015.

Authors:  Sang Taek Heo; Alexander M Tatara; Cristina Jiménez-Ortigosa; Ying Jiang; Russell E Lewis; Jeffrey Tarrand; Frank Tverdek; Nathaniel D Albert; Paul E Verweij; Jacques F Meis; Antonios G Mikos; David S Perlin; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2017-07-15       Impact factor: 9.079

7.  Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?

Authors:  Alison R Novak; Mary E Bradley; Tyree H Kiser; Scott W Mueller
Journal:  Curr Fungal Infect Rep       Date:  2020-03-26

Review 8.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

9.  Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.

Authors:  Jörg Janne Vehreschild; Philipp Koehler; Frédéric Lamoth; Juergen Prattes; Christina Rieger; Bart J A Rijnders; Daniel Teschner
Journal:  Med Mycol       Date:  2021-01-04       Impact factor: 4.076

10.  Epidemiology and Antifungal Susceptibility Patterns of Invasive Fungal Infections (IFIs) in India: A Prospective Observational Study.

Authors:  Yubhisha Dabas; Immaculata Xess; Mragnayani Pandey; Jaweed Ahmed; Janya Sachdev; Azka Iram; Gagandeep Singh; Manoranjan Mahapatra; Rachna Seth; Sameer Bakhshi; Rakesh Kumar; Viveka P Jyotsna; Sandeep Mathur
Journal:  J Fungi (Basel)       Date:  2021-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.